These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 18063925)

  • 1. Testosterone in first-episode schizophrenia.
    Cesková E; Prikryl R; Kaspárek T
    Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia.
    Ko YH; Jung SW; Joe SH; Lee CH; Jung HG; Jung IK; Kim SH; Lee MS
    Psychoneuroendocrinology; 2007 May; 32(4):385-91. PubMed ID: 17395394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study.
    Gross A; Joutsiniemi SL; Rimon R; Appelberg B
    Pharmacopsychiatry; 2004 May; 37(3):119-22. PubMed ID: 15138895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
    Lee BH; Kim YK
    Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
    Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
    Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
    Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
    Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment.
    Cai HL; Fang PF; Li HD; Zhang XH; Hu L; Yang W; Ye HS
    Psychiatry Res; 2011 Jul; 188(2):197-202. PubMed ID: 21146875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study.
    Nakano Y; Yoshimura R; Nakano H; Ikenouchi-Sugita A; Hori H; Umene-Nakano W; Ueda N; Nakamura J
    Hum Psychopharmacol; 2010 Mar; 25(2):139-44. PubMed ID: 20196178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
    Raskin S; Katz G; Zislin Z; Knobler HY; Durst R
    Acta Psychiatr Scand; 2000 Apr; 101(4):334-6. PubMed ID: 10782556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone].
    Sannomiya M; Katsu H; Nakayama K
    Seishin Shinkeigaku Zasshi; 2003; 105(5):643-58. PubMed ID: 12875232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting risperidone improves negative symptoms in stable psychotic patients.
    Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
    J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
    Riedel M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Schennach-Wolff R
    World J Biol Psychiatry; 2012 Jan; 13(1):30-8. PubMed ID: 21568628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.